- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: June 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in June 2027, from ClinicalTrials.gov.
Trial readouts
313 trials: 114 phase 3 (including phase 2/3) and 199 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Jun 2027 | 4D Molecular Therapeutics, Inc. | 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | Macular Neovascularization Secondary to Age-Related Macular Degeneration | Phase 3 | Active not recruiting | NCT06864988 |
| Jun 2027 | Alfasigma S.p.A. | FilgotinibSafety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis i… | Polyarticular Course Juvenile Idiopathic Arthritis | Phase 3 | Recruiting | NCT07554495 |
| Jun 2027 | Alkermes | ALKS 2680 Dose 1, ALKS 2680 Dose 2A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | Narcolepsy Type 1 | Phase 3 | Recruiting | NCT07540897 |
| Jun 2027 | Ascendis Pharma Bone Diseases A/S | Palopegteriparatide Experimental Arm, Palopegteriparatide Control ArmA Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult P… | Hypoparathyroidism, Endocrine System Diseases and 1 more | Phase 3 | Recruiting | NCT07081997 |
| Jun 2027 | Asklepion Pharmaceuticals, LLC | L-citrullineA Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Va… | Sickle Cell Disease | Phase 3 | Not yet recruiting | NCT06989567 |
| Jun 2027 | Aurion Biotech | Combination Product: AURN001 + Y-27632AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction | Corneal Edema, Corneal Endothelial Dysfunction and 2 more | Phase 3 | Active not recruiting | NCT07368959 |
| Jun 2027 | Jiangsu Hengrui Medicine | HRS8179 injection, HRS8179 blank preparation.The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction | Severe Cerebral Edema Following Large Hemispheric Infarction | Phase 2/3 | Recruiting | NCT06732648 |
| Jun 2027 | Sino Biopharmaceutical Limited | Angiotensin II Injection, 0.9% sodium chloride injectionEfficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock | Vasodilatory Shock | Phase 3 | Recruiting | NCT06351150 |
| Jun 2027 | Day One Biopharmaceuticals, Inc. | Tovorafenib, Chemotherapeutic AgentDAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREF… | Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma and 1 more | Phase 3 | Active not recruiting | NCT05566795 |
| Jun 2027 | Denali Therapeutics Inc. | tividenofusp alfaAn Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharido… | Mucopolysaccharidosis II | Phase 2/3 | Enrolling by invitation | NCT06075537 |
| Jun 2027 | Genexine, Inc. | Efepoetin Alfa, Darbepoetin AlfaA Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis | Anemia of Chronic Kidney Disease | Phase 3 | Recruiting | NCT06466785 |
| Jun 2027 | Genfleet Therapeutics (Shanghai) Inc. | GFH375, ChemotherapyPhase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | Phase 3 | Recruiting | NCT07262567 |
| Jun 2027 | Genmab A/s | Epcoritamab, Cyclophosphamide, Rituximab and 3 moreA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphami… | Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | NCT05578976 |
| Jun 2027 | Gilead Sciences | Sacituzumab govitecan-hziy (SG), Pembrolizumab, CapecitabineStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer … | Triple Negative Breast Cancer | Phase 3 | Recruiting | NCT05633654 |
| Jun 2027 | Humacyte, Inc. | Acellular Tissue Engineered Vessel (ATEV), AVFTo Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | End Stage Renal Disease (ESRD) | Phase 3 | Active not recruiting | NCT05908084 |
| Jun 2027 | ITM Solucin GmbH | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) …, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution and 2 moreLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEn… | Neuroendocrine Tumors | Phase 3 | Active not recruiting | NCT04919226 |
| Jun 2027 | Immutep S.A.S. | eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed and 1 moreStudy of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Che… | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Active not recruiting | NCT06726265 |
| Jun 2027 | InnoBM Pharmaceuticals Co., Ltd. | Magnesium Microspheres, cTACEA Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma | Hepatocellular Carcinoma Non-Resectable | Phase 3 | Not yet recruiting | NCT06779461 |
| Jun 2027 | Ionis Pharmaceuticals Inc | OlezarsenA Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Tr… | Familial Chylomicronemia Syndrome | Phase 3 | Active not recruiting | NCT05185843 |
| Jun 2027 | Jiangsu Hengrui Medicine | PyrotinibA Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | Breast Cancer | Phase 3 | Active not recruiting | NCT03980054 |
| Jun 2027 | Lb Pharmaceuticals Inc | LB-102 (50 mg tablet), LB-102 (100 mg tablet)Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | Schizophrenia | Phase 3 | Recruiting | NCT07363577 |
| Jun 2027 | Lantheus Holdings, Inc. | [18F]PI-2620[18F]PI-2620 Phase 3 Histopathological Study | Alzheimer Disease | Phase 3 | Recruiting | NCT05641688 |
| Jun 2027 | Lepu Biopharma Co., Ltd. | MRG004A plus best supportive careA Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancr… | Advanced Pancreatic Cancer | Phase 3 | Not yet recruiting | NCT07138846 |
| Jun 2027 | Lupin Ltd. | Mexiletine granules for prolonged-release oral suspensionThe Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 | Myotonic Dystrophy | Phase 3 | Recruiting | NCT06523400 |
| Jun 2027 | MindRank AI Ltd | MDR-001A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE） | Overweight or Obesity | Phase 3 | Not yet recruiting | NCT07274137 |
| Jun 2027 | Pharvaris Netherlands B.V. | deucrictibantExtension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | Hereditary Angioedema, Hereditary Angioedema Type I and 15 more | Phase 2/3 | Enrolling by invitation | NCT05396105 |
| Jun 2027 | Pharvaris Netherlands B.V. | DeucrictibantStudy of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults… | Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Phase 3 | Recruiting | NCT07266805 |
| Jun 2027 | PleoPharma, Inc. | PP-01, NabiloneEfficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder | Cannabis Withdrawal | Phase 3 | Recruiting | NCT07644052 |
| Jun 2027 | Qilu Pharmaceutical Co., Ltd. | ESG401, Investigator's Choice ChemotherapyA Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | Triple-Negative Breast Cancer (TNBC) | Phase 3 | Recruiting | NCT06732323 |
| Jun 2027 | Qilu Pharmaceutical Co., Ltd. | Voclosporin（QL1074）A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | Lupus Nephritis | Phase 3 | Recruiting | NCT06406205 |
| Jun 2027 | Renibus Therapeutics, Inc. | VeverimerA Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis | CKD, Metabolic Acidosis | Phase 3 | Recruiting | NCT07355062 |
| Jun 2027 | RenovoRx, Inc. | Gemcitabine, nab-paclitaxel, RenovoCathIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Locally Advanced Pancreatic Cancer | Phase 3 | Active not recruiting | NCT03257033 |
| Jun 2027 | Resilience | GutyCareRandomized Controlled Trial Comparing Remote Patient Monitoring vs Standard Care in IBD Patients Initiating or Changing Advanced Therapy | IBD | Phase 3 | Not yet recruiting | NCT07043036 |
| Jun 2027 | SDK Therapeutics, Inc. | Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA)A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (L… | Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia and 7 more | Phase 3 | Not yet recruiting | NCT07296445 |
| Jun 2027 | Savara Inc | MolgramostimInhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Recruiting | NCT06431776 |
| Jun 2027 | Shanghai HEP Pharmaceutical Co., Ltd. | Hepalatide 2.1mgPhase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D | Hepatitis D, Chronic | Phase 3 | Not yet recruiting | NCT07309380 |
| Jun 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, Liposomal doxorubicin, Paclitaxel or TopotecanA Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian C… | Epithelial Ovarian Cancer, Fallopian Tube Cancer and 1 more | Phase 3 | Recruiting | NCT06994195 |
| Jun 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-M07D1, Investigator's choice of chemotherapyA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Ga… | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | NCT07152405 |
| Jun 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, Docetaxel or PaclitaxelA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladd… | Urothelial Carcinoma | Phase 3 | Active not recruiting | NCT06857175 |
| Jun 2027 | Sinotau Pharmaceutical Group | XTR004Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional F… | Coronary Artery Disease(CAD) | Phase 3 | Recruiting | NCT07439133 |
| Jun 2027 | Vedanta Biosciences, Inc. | VE303VE303 for Prevention of Recurrent Clostridioides Difficile Infection | Clostridium Difficile, Clostridium Difficile Infections and 8 more | Phase 3 | Recruiting | NCT06237452 |
| Jun 2027 | Veradermics, Inc | VDPHL01 QD, VDPHL01 BIDSafety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | Androgenetic Alopecia (AGA), Androgenetic Alopecia and 3 more | Phase 3 | Active not recruiting | NCT07146022 |
| Jun 2027 | Verrica Pharmaceuticals Inc. | VP-102Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | Common Warts, Common Warts (Verruca Vulgaris) and 2 more | Phase 3 | Recruiting | NCT07246590 |
| Jun 1, 2027 | Brainfarma Industria Química e Farmacêutica S/A | Experimental: Pregabalin XR, Comparator: Dorene TabsExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | Diabetic Neuropathy, Neuropathic Pain and 1 more | Phase 3 | Recruiting | NCT07712913 |
| Jun 1, 2027 | Chongqing Claruvis Pharmaceutical Co., Ltd. | Recombinant botulinum toxin type A for injection (YY001)A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity | Upper Limb Spasticity | Phase 3 | Recruiting | NCT07478822 |
| Jun 1, 2027 | EBI Anti Sepsis BV | EA-230 90mg/kg/hourA Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Co… | Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG) | Phase 3 | Not yet recruiting | NCT07357675 |
| Jun 1, 2027 | Shanghai Henlius Biotech | HLX22, Pembrolizumab, Trastuzumab and 2 moreA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastri… | Gastroesophageal-junction Cancer, Monoclonal Antibody and 2 more | Phase 3 | Recruiting | NCT06532006 |
| Jun 1, 2027 | Shanghai JMT-Bio Inc. | JMT101, Irinotecan, RegorafenibThe Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | Metastatic Colorectal Cancer (mCRC) | Phase 3 | Not yet recruiting | NCT07134205 |
| Jun 1, 2027 | Sinotau Pharmaceutical Group | Lutetium[177Lu] Oxodotreotide InjectionA Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms | Advanced Neuroendocrine Neoplasm | Phase 2/3 | Recruiting | NCT06398444 |
| Jun 2, 2027 | Novartis | PelabresibAn Extension Study for Patients Previously Enrolled in Studies With Pelabresib | Hematologic Malignancy, Solid Tumor and 1 more | Phase 3 | Recruiting | NCT06401356 |
| Jun 2, 2027 | Sanofi | Dupilumab, Fexofenadine (loratadine if not available)Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERT… | Pruritus | Phase 3 | Recruiting | NCT05263206 |
| Jun 3, 2027 | Novartis | Remibrutinib Dose A, Remibrutinib Dose BA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidraden… | Hidradenitis Suppurativa | Phase 3 | Active not recruiting | NCT06840392 |
| Jun 6, 2027 | Shanghai Henlius Biotech | HLX13, US-sourced YERVOY®, EU-sourced YERVOY®A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Pati… | Hepatocellular Carcinoma (HCC) | Phase 3 | Not yet recruiting | NCT06841185 |
| Jun 6, 2027 | Vertex Pharmaceuticals | CTX001Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | Sickle Cell Disease, Hydroxyurea Failure and 3 more | Phase 3 | Active not recruiting | NCT05329649 |
| Jun 7, 2027 | Cybin IRL Limited | CYB003, Psychological SupportA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Major Depressive Disorder (MDD), Depression in Adults and 4 more | Phase 3 | Recruiting | NCT06793397 |
| Jun 7, 2027 | Jemincare | JYB1904Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. | Chronic Spontaneous Urticaria | Phase 3 | Recruiting | NCT07402213 |
| Jun 7, 2027 | Pfizer | PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adu… | Pneumococcal Disease | Phase 3 | Recruiting | NCT07794748 |
| Jun 7, 2027 | Sanofi | PCV21 vaccine, 20vPCV licensed vaccineLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | Pneumococcal Immunization, Healthy Volunteers | Phase 3 | Recruiting | NCT07348692 |
| Jun 8, 2027 | Johnson & Johnson | GuselkumabTransmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | Crohn's Disease | Phase 3 | Active not recruiting | NCT06408935 |
| Jun 8, 2027 | Takeda Pharmaceutical Company | Vedolizumab, UpadacitinibA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | Crohn's Disease | Phase 3 | Recruiting | NCT06227910 |
| Jun 9, 2027 | Beijing VDJBio Co., LTD. | Recombinant Humanized Anti-Interleukin-6 Receptor Monoclon…Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease | Anti IL-6R, Castleman's Disease, Multicentric | Phase 3 | Recruiting | NCT07872423 |
| Jun 9, 2027 | Novo | CagriSemaResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Diabetes Mellitus, Type 2 | Phase 3 | Recruiting | NCT07817251 |
| Jun 9, 2027 | Vertex Pharmaceuticals | CTX001Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell… | Beta-Thalassemia, Thalassemia and 5 more | Phase 3 | Recruiting | NCT05477563 |
| Jun 11, 2027 | Haisco Pharmaceutical Group Co., Ltd. | HSK39004 Inhalation SuspensionA Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD | COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Not yet recruiting | NCT07658339 |
| Jun 15, 2027 | Applied Biology, Inc. | CS-001Clinical Study of CS-001 As a Treatment for Canities (Grey Hair) | Canities, Grey Hair | Phase 3 | Not yet recruiting | NCT06745336 |
| Jun 15, 2027 | Boehringer Ingelheim | BI 1291583The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | Bronchiectasis | Phase 3 | Recruiting | NCT06872892 |
| Jun 16, 2027 | Amgen | Maridebart cafraglutide, AutoinjectorHome Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Obesity, Overweight | Phase 3 | Not yet recruiting | NCT07871409 |
| Jun 18, 2027 | Regeneron Pharmaceuticals | MibavademabA Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | Monogenic Obesity | Phase 3 | Recruiting | NCT07220772 |
| Jun 21, 2027 | Intra-Cellular Therapies, Inc. | Lumateperone high dose, Lumateperone low doseMulticenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | Irritability Associated With Autism Spectrum Disorder | Phase 3 | Recruiting | NCT06706674 |
| Jun 21, 2027 | Intra-Cellular Therapies, Inc. | Lumateperone high dose, Lumateperone low doseMulticenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | Irritability Associated With Autism Spectrum Disorder | Phase 3 | Recruiting | NCT06690398 |
| Jun 24, 2027 | Merck & Co. | SuvorexantA Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | Insomnia | Phase 3 | Recruiting | NCT06655883 |
| Jun 25, 2027 | AstraZeneca | Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®) and 2 moreOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab… | Severe Asthma | Phase 3 | Active not recruiting | NCT06473779 |
| Jun 28, 2027 | Brainfarma Industria Química e Farmacêutica S/A | dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 …, dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 m…Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common … | Common Cold/Flu, Nasal Congestion and 1 more | Phase 3 | Recruiting | NCT07626437 |
| Jun 28, 2027 | Bristol-Myers Squibb | Xanomeline/Trospium ChlorideA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants … | Mania, Bipolar Disorder | Phase 3 | Recruiting | NCT07140913 |
| Jun 29, 2027 | Psicofarma, S.A. De C.V. | App AURORA (Digital Therapy) + conventional treatment, Pharmacological conventional treatmentClinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device in Adult Patients With Moderate to Severe Generaliz… | General Anxiety Disorder | Phase 3 | Recruiting | NCT07477990 |
| Jun 30, 2027 | Amgen | EtelcalcetideA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | Secondary Hyperparathyroidism | Phase 3 | Recruiting | NCT03969329 |
| Jun 30, 2027 | Amgen | Sotorasib, PembrolizumabA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Parti… | Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | NCT05920356 |
| Jun 30, 2027 | Ascentage Pharma Group International | olverembatinib, BosutinibStudy of Olverembatinib (HQP1351) in Patients With CML-CP | Chronic Myeloid Leukemia, CML and 1 more | Phase 3 | Recruiting | NCT06423911 |
| Jun 30, 2027 | AstraZeneca | Durvalumab, cisplatin + fluorouracil, cisplatin + capecitabine and 1 moreStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | Esophageal Squamous Cell Carcinoma | Phase 3 | Active not recruiting | NCT04550260 |
| Jun 30, 2027 | BeOne Medicines Ltd. | Tislelizumab, Cisplatin, Gemcitabine Hydrochloride and 1 moreStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma | Urothelial Carcinoma | Phase 3 | Active not recruiting | NCT03967977 |
| Jun 30, 2027 | Belite Bio, Inc | TinlarebantPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | Geographic Atrophy | Phase 3 | Active not recruiting | NCT05949593 |
| Jun 30, 2027 | Csl Ltd | CSL511 Fibrinogen concentrate (human), CryoprecipitatePhase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery | Acquired Fibrinogen Deficiency | Phase 3 | Recruiting | NCT06617897 |
| Jun 30, 2027 | CSPC Pharmaceutical Group | Bempedoic Acid TabletA Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid | Primary Hyperlipidemia | Phase 3 | Not yet recruiting | NCT07623915 |
| Jun 30, 2027 | Cutiss Ag | denovoSkin(TM), STSGPhase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | Burns | Phase 3 | Recruiting | NCT06745557 |
| Jun 30, 2027 | Cali Pharmaceuticals LLC | CPL-01Phase 3 Bunionectomy Study | Postoperative Pain, Bunion | Phase 3 | Not yet recruiting | NCT07490496 |
| Jun 30, 2027 | Changchun GeneScience Pharmaceutical Co., Ltd. | Nano-crystalline Megestrol Acetate Oral Suspension, Standard TherapyClinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Termino… | Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy | Phase 3 | Not yet recruiting | NCT06961188 |
| Jun 30, 2027 | Changchun GeneScience Pharmaceutical Co., Ltd. | Nanocrystalline Megestrol Acetate, Standard Antitumor TherapyNanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma | Cachexia, Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | NCT07356037 |
| Jun 30, 2027 | Changchun GeneScience Pharmaceutical Co., Ltd. | Nano-crystalline Megestrol Acetate Oral Suspension, Standard TherapyNanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | Phase 3 | Recruiting | NCT07150663 |
| Jun 30, 2027 | Changchun GeneScience Pharmaceutical Co., Ltd. | Nano-crystalline Megestrol Acetate Oral Suspension, standard treatmentNano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery. | Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors | Phase 3 | Not yet recruiting | NCT06772428 |
| Jun 30, 2027 | Cidara Therapeutics | MK-1406A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | Influenza | Phase 3 | Recruiting | NCT07159763 |
| Jun 30, 2027 | Doron Therapeutics Inc. | PTP-01A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | Knee Osteoarthritis | Phase 3 | Recruiting | NCT07219771 |
| Jun 30, 2027 | Gan & Lee Pharmaceuticals Co., Ltd. | GZR18, Semaglutide(Wegovy® )Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subject… | Obesity/Overweight in Adult | Phase 3 | Recruiting | NCT07150975 |
| Jun 30, 2027 | Gipfel Life Sciences GmbH | Galunisertib + Nerandomilast CombinationThis Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomi… | ALS (Amyotrophic Lateral Sclerosis) | Phase 2/3 | Not yet recruiting | NCT07321860 |
| Jun 30, 2027 | HELP Therapeutics Co., Ltd. | HiCM-188 therapy, CABG surgeryA Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced He… | Heart Failure | Phase 3 | Recruiting | NCT07496372 |
| Jun 30, 2027 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Roflumilast Foam 0.3%Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis | Seborrheic Dermatitis | Phase 3 | Not yet recruiting | NCT07683806 |
| Jun 30, 2027 | Roche Holding | Alectinib, Atezolizumab, Pemetrexed and 9 moreA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (N… | Non-Small Cell Lung Cancer | Phase 2/3 | Active not recruiting | NCT03178552 |
| Jun 30, 2027 | Roche Holding | PDS With Ranibizumab (100 mg/mL), Ranibizumab (10 mg/mL)A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With N… | Neovascular Age-related Macular Degeneration, nAMD | Phase 3 | Active not recruiting | NCT05562947 |
| Jun 30, 2027 | Roche Holding | AstegolimabA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | Phase 3 | Active not recruiting | NCT05878769 |
| Jun 30, 2027 | Roche Holding | Atezolizumab, Bevacizumab, Pemetrexed and 2 moreAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella… | Neoplasms | Phase 3 | Active not recruiting | NCT05112965 |
| Jun 30, 2027 | IBSA Institut Biochimique | Sodium hyaluronate solution - 3.36%, Sterile buffered solutionA Study to Evaluate Efficacy and Safety of a Single Intra-Articular Injection of HL-01 in the Treatment of Pain in Symptomatic Knee Osteoart… | Osteo Arthritis of the Knee | Phase 3 | Not yet recruiting | NCT07819461 |
| Jun 30, 2027 | Il-Yang Pharm. Co., Ltd. | Radotinib HClA Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs | Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase and 2 more | Phase 3 | Recruiting | NCT03459534 |
| Jun 30, 2027 | Innovent Biologics | IBI343A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cance… | Pancreatic Cancer | Phase 3 | Recruiting | NCT07066098 |
| Jun 30, 2027 | Johnson & Johnson | NipocalimabA Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | Myasthenia Gravis | Phase 2/3 | Recruiting | NCT05265273 |
| Jun 30, 2027 | Jiangsu Hengrui Medicine | SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ IrinotecanSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-li… | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | NCT06123494 |
| Jun 30, 2027 | Kexing Biopharm Co., Ltd. | Human interferon α1b Inhalation SolutionHuman Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections | Respiratory Syncytial Virus Infections | Phase 3 | Recruiting | NCT06363370 |
| Jun 30, 2027 | Lunan Better Pharmaceutical Co., LTD. | Isosorbide oral solutionEfficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease | Meniere´s Disease | Phase 2/3 | Not yet recruiting | NCT06765993 |
| Jun 30, 2027 | MeiraGTx Ocular UK Ltd | AAV5-hRKp.RPGRA Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa | Retinitis Pigmentosa | Phase 3 | Active not recruiting | NCT05926583 |
| Jun 30, 2027 | MicuRx | contezolid acefosamil (IV)/contezolid (PO), Linezolid (IV and PO)Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With… | Diabetic Foot Infection | Phase 3 | Recruiting | NCT05369052 |
| Jun 30, 2027 | Mirum Pharmaceuticals | Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mgA Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | Chronic Hepatitis D Infection | Phase 3 | Recruiting | NCT07200908 |
| Jun 30, 2027 | Norroy Bioscience Co., LTD | 68-Ga-NYM032Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. | Prostate Cancer (Diagnosis) | Phase 3 | Recruiting | NCT07615101 |
| Jun 30, 2027 | Qilu Pharmaceutical Co., Ltd. | ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatm…A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer | Metastatic Breast Cancer | Phase 3 | Recruiting | NCT06383767 |
| Jun 30, 2027 | Shanghai Hutchison Pharmaceuticals Limited | SHPL-49 InjectionPhase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke | Acute Ischemic Stroke | Phase 3 | Recruiting | NCT07241520 |
| Jun 30, 2027 | StemCyte, Inc. | REGENECYTEA Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition | Long COVID, Post-COVID-19 Condition and 2 more | Phase 3 | Not yet recruiting | NCT07184385 |
| Jun 30, 2027 | Thryv Therapeutics, Inc. | baseline lead-in, THRV-1268Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) | Long QT Syndrome (LQTS) 2 | Phase 2/3 | Recruiting | NCT07277582 |
| Jun 2027 | 4D Molecular Therapeutics, Inc. | 4D-7104D-710 in Adult Patients With Cystic Fibrosis | Cystic Fibrosis Lung | Phase 2 | Recruiting | NCT05248230 |
| Jun 2027 | ARS Pharmaceuticals, Inc. | 0.5 mg epinephrine, 1 mg epinephrineAn Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria | Urticaria Chronic | Phase 2 | Recruiting | NCT06927999 |
| Jun 2027 | AbbVie | Carfilzomib, Venetoclax, DexamethasoneStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | Multiple Myeloma | Phase 2 | Active not recruiting | NCT02899052 |
| Jun 2027 | Aimmune Nestlé Health Science US R&D, LLC | NHS7108, Zenpep®A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. | Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) and 2 more | Phase 2 | Recruiting | NCT07559175 |
| Jun 2027 | Akebia Therapeutics, Inc. | Praliciguat (Part A), Praliciguat (Part B)A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | NCT07268638 |
| Jun 2027 | Arcturus Therapeutics | ARCT-032Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis | Cystic Fibrosis, CFTR Gene Mutation | Phase 2 | Recruiting | NCT06747858 |
| Jun 2027 | Arrowhead Pharmaceuticals | ARO-MAPT-SCStudy of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease | Alzheimer Disease, Alzheimer Disease, Early Onset | Phase 1/2 | Recruiting | NCT07221344 |
| Jun 2027 | Assembly Biosciences, INC. | ABI-6250A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection | Chronic Hepatitis D Infection | Phase 2 | Not yet recruiting | NCT07762027 |
| Jun 2027 | Avalyn Pharma Inc. | AP01A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | Pulmonary Fibrosis, Progressive Pulmonary Fibrosis and 8 more | Phase 2 | Active not recruiting | NCT06329401 |
| Jun 2027 | Basking Biosciences, Inc. | BB-031Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | Acute Ischemic Stroke | Phase 2 | Recruiting | NCT06226805 |
| Jun 2027 | BeBetter Med Inc | BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection and 1 moreStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations | Non Small Cell Lung Cancer | Phase 2 | Recruiting | NCT06514027 |
| Jun 2027 | BioNTech | BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide and 3 moreSafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemoth… | Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer | Phase 2 | Active not recruiting | NCT06449209 |
| Jun 2027 | BioNTech | BNT166aA Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine … | Mpox (Monkeypox), Smallpox and 1 more | Phase 2 | Recruiting | NCT07379580 |
| Jun 2027 | Biomea Fusion, Inc. | icovamenib 100 mgPhase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based The… | Type 2 Diabetes | Phase 2 | Recruiting | NCT07502508 |
| Jun 2027 | Biophytis | BIO101, SemaglutideTesting the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weigh… | Muscle Wasting, Obesity & Overweight and 1 more | Phase 2 | Not yet recruiting | NCT07411378 |
| Jun 2027 | Boston Scientific | TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapyTheraSphere With Durvalumab and Tremelimumab for HCC | Hepatocellular Carcinoma | Phase 2 | Active not recruiting | NCT05063565 |
| Jun 2027 | Broadenbio Ltd., Co. | BB102A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma | Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | NCT07239986 |
| Jun 2027 | Sino Biopharmaceutical Limited | TQB2930 injection +(Oxaliplatin for injection + Capecitabi…, TQB2930 injection +(Oxaliplatin for injection + Capecitabi…A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unrese… | Colorectal Cancer | Phase 1/2 | Recruiting | NCT07653685 |
| Jun 2027 | ConSynance Therapeutics | CSTI-500A Study of CSTI-500 in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | Phase 2 | Recruiting | NCT07348601 |
| Jun 2027 | Corvus Pharmaceuticals, Inc. | SoquelitinibStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD | Atopic Dermatitis, Atopic Dermatitis Eczema and 2 more | Phase 2 | Recruiting | NCT07441395 |
| Jun 2027 | Cyllene Therapeutics | EG110ADose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinen… | Neurogenic Detrusor Overactivity, Spinal Cord Injuries | Phase 1/2 | Recruiting | NCT06596291 |
| Jun 2027 | CytoAgents, Inc. | CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg and 2 moreStudy of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy | Cytokine Release Syndrome | Phase 1/2 | Recruiting | NCT05905328 |
| Jun 2027 | Direct Biologics, LLC | DB-3QDB-3Q for the Treatment of Medically Refractory Crohn's Disease | Crohn Disease (CD) | Phase 2 | Recruiting | NCT07625293 |
| Jun 2027 | Dizal Pharmaceuticals | DZD6008, Pemetrexed, Carboplatin and 1 moreDZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) | Non Small Cell Lung Cancer | Phase 1/2 | Recruiting | NCT07070440 |
| Jun 2027 | Dynavax Technologies Corp | Z-1018, ShingrixSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and O… | Shingles, Herpes Zoster and 1 more | Phase 1/2 | Active not recruiting | NCT06569823 |
| Jun 2027 | Elgan Pharma Ltd. | ELGN-2112Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA | Intestinal Malabsorption | Phase 2 | Recruiting | NCT05904626 |
| Jun 2027 | Eli Lilly and Company | LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease | Crohn Disease | Phase 2 | Recruiting | NCT07483099 |
| Jun 2027 | Eli Lilly and Company | Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | Colitis, Ulcerative, Crohn Disease | Phase 2 | Recruiting | NCT07483073 |
| Jun 2027 | Eli Lilly and Company | LY4005130A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) | Alopecia Areata | Phase 2 | Recruiting | NCT07533006 |
| Jun 2027 | Excyte Biopharma Ltd | YK012Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | Phase 1/2 | Recruiting | NCT07010835 |
| Jun 2027 | Fujian Shengdi Pharmaceutical Co., Ltd. | HRS-7249 injection set, SHR-1918 injection setPhase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Ris… | Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | Phase 2 | Active not recruiting | NCT07308392 |
| Jun 2027 | Gesynta Pharma AB | VipoglanstatA Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis | Endometriosis | Phase 2 | Active not recruiting | NCT07260669 |
| Jun 2027 | Great Novel Therapeutics Biotech & Medicals Corporation | ChidamideChidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) | Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | Recruiting | NCT05833724 |
| Jun 2027 | Jiangsu Hengrui Medicine | SHR-2173 Injection, SHR-2173 Injection Blank PreparationA Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis | Active Lupus Nephritis | Phase 2 | Recruiting | NCT07229742 |
| Jun 2027 | Jiangsu Hengrui Medicine | SHR-1819 Injection, SHR-1819 Injection Blank PreparationA Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | Phase 2 | Active not recruiting | NCT07321951 |
| Jun 2027 | Jiangsu Hengrui Medicine | SHR-1139 InjectionA Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Phase 2 | Not yet recruiting | NCT07444684 |
| Jun 2027 | Haisco Pharmaceutical Group Co., Ltd. | HSK39297 tabletsLong-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Recruiting | NCT06745622 |
| Jun 2027 | Healx Limited | HLX-1502A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | Neurofibromatosis Type 1 | Phase 2 | Recruiting | NCT06541847 |
| Jun 2027 | Huons Co., Ltd. | HUC1-394Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease | Dry Eye Disease (DED) | Phase 2 | Recruiting | NCT07656688 |
| Jun 2027 | Idorsia Pharmaceuticals Ltd. | ACT-777991A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo | Non-Segmental Vitiligo | Phase 2 | Not yet recruiting | NCT07667569 |
| Jun 2027 | Immuneering Corp | IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment…, IMM-1-104 + modified FOLFIRINOX (Treatment Group C) and 2 moreA Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor, Pancreatic Adenocarcinoma and 2 more | Phase 1/2 | Active not recruiting | NCT05585320 |
| Jun 2027 | Innate Pharma SA | IPH5201 + durvalumab + standard chemotherapyIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | Non Small Cell Lung Cancer | Phase 2 | Recruiting | NCT05742607 |
| Jun 2027 | Jiangsu Hengrui Medicine | SHR-9803A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Not yet recruiting | NCT06906731 |
| Jun 2027 | Karyopharm Therapeutics Inc. | Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib and 2 moreA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | Myelofibrosis, Moderate Thrombocytopenia and 1 more | Phase 2 | Recruiting | NCT05980806 |
| Jun 2027 | Kymera Therapeutics | KT-621A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | Phase 2 | Active not recruiting | NCT07217015 |
| Jun 2027 | Locus Biosciences | LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose and 2 moreA Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) | Urinary Tract Infections | Phase 2 | Recruiting | NCT05488340 |
| Jun 2027 | Lumara Bio Oncologics GmbH | [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of … | Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC) and 7 more | Phase 1/2 | Recruiting | NCT05706129 |
| Jun 2027 | MeiraGTx Holdings plc | AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, AAV2-hAQP1 Concentration 3 and 1 moreA Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | Phase 2 | Active not recruiting | NCT05926765 |
| Jun 2027 | MiNK Therapeutics, Inc. | agenT-797A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic R… | Pneumonia | Phase 2 | Recruiting | NCT07615010 |
| Jun 2027 | Nanjing IASO Biotechnology Co., Ltd. | Eque-cel CAR-T TherapyStudy of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis | AL Amyloidosis | Phase 2 | Not yet recruiting | NCT07055724 |
| Jun 2027 | NovaSight | TrackSightAssessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children ״DYMOND Study״ | Myopia | Phase 2 | Recruiting | NCT07390500 |
| Jun 2027 | OBI Pharma, Inc. | OBI-992A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Active not recruiting | NCT06480240 |
| Jun 2027 | Oruka Therapeutics, Inc. | ORKA-001Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Phase 2 | Active not recruiting | NCT07290569 |
| Jun 2027 | Pierre Fabre Medicament | TabelecleucelA Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD) and 9 more | Phase 2 | Active not recruiting | NCT04554914 |
| Jun 2027 | Qilu Pharmaceutical Co., Ltd. | QL2401 25 mg, QL2401 50 mg, QL2401 100 mgTo Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3) | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Not yet recruiting | NCT07620366 |
| Jun 2027 | Qilu Pharmaceutical Co., Ltd. | QLC5513 IV infusion, QL1706, IV infusion, platinum, IV infusionStudy of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors | Metastatic Solid Tumors | Phase 1/2 | Not yet recruiting | NCT07272590 |
| Jun 2027 | ReCellience15, Inc | Pentadecanoic AcidEffect of Pentadecanoic Acid Supplementation on Red Blood Cell Health and Biological Aging in Healthy Older Adults | Red Blood Cell Health, Biological Aging and 1 more | Phase 2 | Not yet recruiting | NCT07812792 |
| Jun 2027 | Recursion Pharmaceuticals | REC-4881Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Familial Adenomatous Polyposis | Phase 1/2 | Recruiting | NCT05552755 |
| Jun 2027 | Revolution Medicines, Inc. | RMC-6291, RMC-6236, Pembrolizumab and 4 moreStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC and 3 more | Phase 1/2 | Recruiting | NCT06162221 |
| Jun 2027 | Jiangsu Hengrui Medicine | HRS-7058A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors | Solid Tumors | Phase 2 | Recruiting | NCT07032077 |
| Jun 2027 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | HL-1186, Pregabalin capsuleA Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia | Postherpetic Neuralgia ( PHN ) | Phase 2 | Recruiting | NCT07758920 |
| Jun 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed DisodiumA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carc… | Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and 1 more | Phase 2 | Recruiting | NCT06475300 |
| Jun 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma | Chordoma | Phase 2 | Active not recruiting | NCT06787664 |
| Jun 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, Osimertinib Mesylate TabletsA Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Can… | Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | NCT06498986 |
| Jun 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, PD-1 monoclonal antibodyA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid … | Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | NCT06437522 |
| Jun 2027 | Sichuan Huiyu Pharmaceutical Co., Ltd | Test product HY0001a for injectionA Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors | Solid Tumor | Phase 1/2 | Recruiting | NCT07069062 |
| Jun 2027 | Spyre Therapeutics, Inc. | SPY001, SPY002, SPY003A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | Ulcerative Colitis, Inflammatory Bowel Diseases and 2 more | Phase 2 | Recruiting | NCT07012395 |
| Jun 2027 | Sundance Biosciences, Inc. | SUN-627A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) | Primary Progressive Multiple Sclerosis, Primary Progressive MS and 7 more | Phase 2 | Recruiting | NCT07840326 |
| Jun 2027 | Tango Therapeutics, Inc. | TNG462, PembrolizumabSafety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Locally Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT05732831 |
| Jun 2027 | Tango Therapeutics, Inc. | TNG462, RMC-9805, RMC-6236 and 2 moreStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma and 6 more | Phase 1/2 | Recruiting | NCT06922591 |
| Jun 2027 | Thiogenesis Therapeutics, Corp. | TTI-0102: cysteamine-pantetheine disulfide, D-MannitolA Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS) | Leigh Syndrome | Phase 2 | Not yet recruiting | NCT06990984 |
| Jun 2027 | Tiger Biosciences, LLC. | PRFMEvaluating Autologous Platelet-Rich Fibrin Plasma for Chronic Diabetic Foot Ulcers | Diabetic Foot Ulcer (DFU), Ulcer and 2 more | Phase 1/2 | Not yet recruiting | NCT07840378 |
| Jun 2027 | Tiger Biosciences, LLC. | PRFMEvaluating Autologous Platelet-Rich Fibrin Plasma for Chronic Lower Extremity Ulcers | Lower Extremity, Chronic Ulcers and 3 more | Phase 1/2 | Not yet recruiting | NCT07862335 |
| Jun 2027 | Verastem Oncology | VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab react…A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | Phase 2 | Recruiting | NCT07644559 |
| Jun 2027 | Verastem Oncology | VS-7375, cetuximab, panitumumab and 1 moreA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Colorectal Cancer | Phase 2 | Recruiting | NCT07659795 |
| Jun 2027 | Verastem Oncology | VS-7375A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Phase 2 | Recruiting | NCT07659782 |
| Jun 2027 | Vima Therapeutics | VIM0423A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsiv… | PARKINSON DISEASE (Disorder) | Phase 2 | Recruiting | NCT07804615 |
| Jun 2027 | Vironexis Biotherapeutics Inc. | Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 and 1 moreGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma and 11 more | Phase 1/2 | Recruiting | NCT06533579 |
| Jun 2027 | Yuhan | YH32364Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | EGFR Overexpression, Locally Advanced Solid Tumor and 1 more | Phase 1/2 | Recruiting | NCT06975410 |
| Jun 2027 | vTv Therapeutics Inc. | Cadisegliatin 800 mg QDCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems | Type 1 Diabetes (T1D) | Phase 2 | Not yet recruiting | NCT07616206 |
| Jun 1, 2027 | Afasci Inc | AFA-281A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder | Alcohol Abuse, Alcohol Abuse/addiction and 4 more | Phase 2 | Not yet recruiting | NCT06710431 |
| Jun 1, 2027 | Ascentage Pharma Group International | APG-115, APG-2575APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | Neuroblastoma, Solid Tumor | Phase 1/2 | Recruiting | NCT05701306 |
| Jun 1, 2027 | Changchun Intellicrown Pharmaceutical Co. LTD | IMM-H014To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1/2 | Not yet recruiting | NCT07016633 |
| Jun 1, 2027 | Criterium, Inc. | Tucatinib, Eribulin, TrastuzumabTucatinib+Trastuzumab+Eribulin in HER2+ MBC | Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer | Phase 2 | Active not recruiting | NCT05458674 |
| Jun 1, 2027 | Eikon Therapeutics, Inc. | IMP1734A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT06253130 |
| Jun 1, 2027 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1803 injectionA Study of GR1803 in Systemic Lupus Erythematosus | Systemic Lupus Erthematosus, Auto Immune Disease | Phase 1/2 | Recruiting | NCT07348055 |
| Jun 1, 2027 | Prana Therapies Inc | PRA-216PRA-216 COPD Safety and Biomarker Study | Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Not yet recruiting | NCT07730281 |
| Jun 1, 2027 | Qilu Pharmaceutical Co., Ltd. | QLS12010QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa | Adults With Moderate-to-severe Hidradenitis Suppurativa | Phase 2 | Not yet recruiting | NCT07417917 |
| Jun 1, 2027 | Shanghai Henlius Biotech | HLX22, Trastuzumab DeruxtecanA Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic B… | HER2-low Hormone Receptor Positive Breast Cancer | Phase 2 | Recruiting | NCT06832202 |
| Jun 1, 2027 | Shanghai Juncell Therapeutics | Autologous Tumor Infiltrating LymphocytesA Phase II Study of GC101 in NSCLC | Non Small Cell Lung Cancer | Phase 2 | Recruiting | NCT07560111 |
| Jun 1, 2027 | Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | Sublingual Film for Dermatophagoides pteronyssinusEfficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites | Allergic Rhinitis Due to Dust Mite | Phase 2 | Not yet recruiting | NCT07475715 |
| Jun 3, 2027 | Chiesi Farmaceutici S.p.A. | CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a, CHF718 pMDI with HFA-134aTherapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | Asthma | Phase 2 | Recruiting | NCT07301736 |
| Jun 4, 2027 | LucasBio | LB-DTK-MVEvaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated D… | BKV Infection, EBV Infection and 1 more | Phase 1/2 | Recruiting | NCT07670468 |
| Jun 4, 2027 | The United Bio-Technology (Hengqin) Co., Ltd. | UBT251A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Recruiting | NCT07145151 |
| Jun 7, 2027 | AstraZeneca | TozorakimabDose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Cort… | Asthma | Phase 2 | Recruiting | NCT06932263 |
| Jun 8, 2027 | Roche Holding | FenebrutinibA Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Mul… | Relapsing Multiple Sclerosis | Phase 2 | Recruiting | NCT07161258 |
| Jun 10, 2027 | Merck & Co. | MK-6916, Hydrocodone/acetaminophen (HB/APAP), Rescue MedicationA Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007) | Pain Management | Phase 2 | Not yet recruiting | NCT07862595 |
| Jun 11, 2027 | Merck & Co. | Paclitaxel, Irinotecan, Pembrolizumab and 9 moreA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previousl… | Esophageal Squamous Cell Carcinoma | Phase 1/2 | Recruiting | NCT05319730 |
| Jun 11, 2027 | GSK | VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed …, Dolutegravir / Lamivudine (DTG/3TC)A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | HIV Infections | Phase 2 | Recruiting | NCT07202546 |
| Jun 12, 2027 | Merck & Co. | I-DXd, Rescue MedicationA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) | Oesophageal Squamous Cell Carcinoma | Phase 1/2 | Recruiting | NCT07405151 |
| Jun 14, 2027 | Beijing Biotech | Cyclophosphamide, Fludarabine, EB-CAR30-NK and 3 moreTarget-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma | B2 Thymoma, Thymic Carcinoma | Phase 1/2 | Recruiting | NCT07598955 |
| Jun 14, 2027 | Beijing Biotech | EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, CyclophosphamideDual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | Unresectable Melanoma, Metastatic Cutaneous Melanoma and 1 more | Phase 1/2 | Recruiting | NCT07627698 |
| Jun 14, 2027 | Beijing Biotech | Dual-target CAR-NK cell product, Cyclophosphamide, supportiveDual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma and 2 more | Phase 1/2 | Recruiting | NCT07617753 |
| Jun 14, 2027 | Johnson & Johnson | JNJ-79635322A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | Phase 2 | Active not recruiting | NCT07266441 |
| Jun 14, 2027 | Novo | NNC0662-0419, SemaglutideA Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Obesity | Phase 2 | Active not recruiting | NCT07639021 |
| Jun 15, 2027 | Applied Biology, Inc. | CS-002Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities) | Canities, Grey Hair | Phase 1/2 | Not yet recruiting | NCT07166354 |
| Jun 15, 2027 | CARsgen Therapeutics Co., Ltd. | CT071Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL | Multiple Myeloma, Primary Plasma Cell Leukemia | Phase 1/2 | Not yet recruiting | NCT06333509 |
| Jun 15, 2027 | CSPC Pharmaceutical Group | SYS6010 jnjection, monotherapy chemotherapy, SYH2051 tabletsClinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | Advanced Solid Tumors, Breast Cancer | Phase 1/2 | Not yet recruiting | NCT06775236 |
| Jun 15, 2027 | Chugai Pharmaceutical Co. | Simulated Inadvertent Gluten Exposure (SIGE) capsule, DONQ52Study of DONQ52 in Active Celiac Disease | Celiac Disease | Phase 2 | Recruiting | NCT07239336 |
| Jun 15, 2027 | Enalare Therapeutics Inc. | ENA-001ENA-001 for Post Operative Respiratory Depression (PORD) | Respiratory Depression | Phase 2 | Not yet recruiting | NCT06137638 |
| Jun 15, 2027 | Merck & Co. | TulisokibartA Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | Radiographic Axial Spondyloarthritis | Phase 2 | Recruiting | NCT07133633 |
| Jun 15, 2027 | Neurona Therapeutics | NRTX-1001A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) | Epilepsy, Temporal Lobe | Phase 1/2 | Recruiting | NCT06422923 |
| Jun 15, 2027 | S1 Biopharma, Inc. | S1B-509 low dose, S1B-509 High DoseOne-Year Study of S1B-509 vs Placebo for Weight Loss | Obesity | Phase 2 | Not yet recruiting | NCT06517797 |
| Jun 18, 2027 | Shanghai Henlius Biotech | HLX43 dose 1, HLX43 dose 2A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer | Non Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | Recruiting | NCT07253142 |
| Jun 19, 2027 | Yuhan | LesigerceptPhase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines | Allergic Diseases, Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | NCT07415551 |
| Jun 20, 2027 | Ausper Biopharma Co., Ltd. | AHB-137A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B | Chronic Hepatitis B | Phase 2 | Recruiting | NCT07635186 |
| Jun 20, 2027 | Crossignal Therapeutics, Inc. | CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | Solid Tumor, Adult, Colorectal Cancer and 1 more | Phase 1/2 | Recruiting | NCT06598007 |
| Jun 20, 2027 | PT. Prodia Stem Cell Indonesia | Allogeneic Umbilical Cord Mesenchymal Stem CellUmbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B | Liver Cirrhoses | Phase 1/2 | Enrolling by invitation | NCT04357600 |
| Jun 21, 2027 | GSK | Mo-Rez, Dostarlimab, BevacizumabA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | Tumours, Gynecological | Phase 1/2 | Recruiting | NCT06796907 |
| Jun 21, 2027 | Sanofi | Lunsekimig, Short-Acting Beta Agonists (SABA), Fluticasone/Salmeterol and 2 moreStudy of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Asthma | Phase 2 | Active not recruiting | NCT06676319 |
| Jun 22, 2027 | Novartis | AlpelisibStudy Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Partici… | PIK3CA-related Overgrowth Spectrum (PROS) | Phase 2 | Active not recruiting | NCT04980833 |
| Jun 22, 2027 | Pfizer | Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3 and 4 moreA Study to Learn About mRNA Vaccines Against Influenza in Adults | Healthy Adults | Phase 2 | Recruiting | NCT07431853 |
| Jun 23, 2027 | Almirall, S.A. | LAD603A Study of LAD603 in Adults With Alopecia Areata | Alopecia Areata | Phase 2 | Recruiting | NCT07311564 |
| Jun 23, 2027 | Blueprint Medicines Corp | Avapritinib(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versu… | Indolent Systemic Mastocytosis | Phase 2 | Active not recruiting | NCT03731260 |
| Jun 24, 2027 | Ever Supreme Bio Technology Co., Ltd. | Allogeneic umbilical cord mesenchymal stem cells, Control groupEvaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardia… | ST Elevation Myocardial Infarction | Phase 2 | Recruiting | NCT06147986 |
| Jun 25, 2027 | Apellis Pharmaceuticals, Inc. | APL-3007, pegcetacoplan (APL-2)A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of… | Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | Recruiting | NCT07215390 |
| Jun 26, 2027 | Boehringer Ingelheim | BI 3034701A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight | Obesity, Overweight | Phase 2 | Active not recruiting | NCT07662122 |
| Jun 26, 2027 | Qilu Pharmaceutical Co., Ltd. | Albipagrastim alfPhase II Study of QLC2519 in Pediatric Solid Tumor Participants | Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN) and 1 more | Phase 2 | Recruiting | NCT07724756 |
| Jun 28, 2027 | Johnson & Johnson | JNJ-88545223A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis | Arthritis, Psoriatic | Phase 2 | Recruiting | NCT07321873 |
| Jun 30, 2027 | Abbisko Therapeutics Co, Ltd | ABSK-011+BSCABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | NCT07327034 |
| Jun 30, 2027 | Agiana Pharmaceuticals | AGP100Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | Catecholaminergic Polymorphic Ventricular Tachycardia | Phase 2 | Recruiting | NCT07263139 |
| Jun 30, 2027 | AiViva BioPharma, Inc. | AIV007, EYLEA® (aflibercept) Injection 2 mg (0.05mL)Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration | Neovascular (Wet) Age-Related Macular Degeneration | Phase 2 | Not yet recruiting | NCT07557121 |
| Jun 30, 2027 | Alentis Therapeutics AG | ALE.F02, Rituximab, GlucoCorticoid and 2 moreRescue of Nephrons With ALE.F02 (RENAL-F02) | Glomerulonephritis Rapidly Progressive | Phase 2 | Recruiting | NCT06047171 |
| Jun 30, 2027 | Alnylam Pharmaceuticals | ALN-6400HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB | Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB) | Phase 2 | Recruiting | NCT07575308 |
| Jun 30, 2027 | Amckaus PTY LTD. | Rocuronium (0.6mg/kg), vecuronium bromide (0.1mg/kg)A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular Blockade | Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery, Reversing Rocuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery | Phase 2 | Not yet recruiting | NCT07595393 |
| Jun 30, 2027 | Aplagon Oy | APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH), APAC dose level 1: 0.25 mg/kg, and 3 moreSafety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia | Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia | Phase 2 | Recruiting | NCT07352800 |
| Jun 30, 2027 | Aptabio Therapeutics, Inc. | IsuzinaxibEfficacy and Safety Study of Isuzinaxib in Subjects With DKD | Diabetic Kidney Disease (DKD) | Phase 2 | Recruiting | NCT06962098 |
| Jun 30, 2027 | Astellas Pharma | zolbetuximab, oxaliplatin, leucovorin and 5 moreA Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer | Pharmacokinetics of Zolbetuximab, Gastric Cancer and 3 more | Phase 2 | Active not recruiting | NCT03505320 |
| Jun 30, 2027 | AstraZeneca | Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), BevacizumabA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Metastatic Colorectal Cancer | Phase 2 | Recruiting | NCT06792695 |
| Jun 30, 2027 | AstraZeneca | AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapyFirst in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Hepatocellular Carcinoma | Phase 1/2 | Recruiting | NCT06795022 |
| Jun 30, 2027 | Azafaros B.V. | AZ-3102A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease | GM2 Gangliosidosis, Niemann-Pick Type C Disease | Phase 2 | Active not recruiting | NCT07399704 |
| Jun 30, 2027 | BeOne Medicines Ltd. | TacabrutidegTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | B-cell Malignancy, Non-Hodgkin Lymphoma and 7 more | Phase 1/2 | Recruiting | NCT05294731 |
| Jun 30, 2027 | Belief BioMed (Beijing) Co., Ltd | Single dose intravenous of BBM-D101A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. | DMD | Phase 1/2 | Recruiting | NCT07058662 |
| Jun 30, 2027 | Biozeus Biopharmaceutical S.A. | BZ371A (0.5 ml), BZ371A (1.0 ml)Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder | Female Sexual Arousal Disorder, Female Sexual Dysfunction (FSD) | Phase 2 | Not yet recruiting | NCT06651541 |
| Jun 30, 2027 | Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. | ALT001ALT001 in Patients With Ischemic Stroke in the Sequelae Stage | Ischemic Stroke in the Sequelae Stage | Phase 2 | Not yet recruiting | NCT07841496 |
| Jun 30, 2027 | Dasher Neuroscience Inc. | YA-101A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy | Multiple System Atrophy | Phase 2 | Active not recruiting | NCT06848231 |
| Jun 30, 2027 | DualityBio Inc. | DB-2304, PrednisoneA Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants | Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus | Phase 1/2 | Recruiting | NCT06625671 |
| Jun 30, 2027 | Eloxx Pharmaceuticals, Inc. | ExalurenEXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety | Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive | Phase 2 | Recruiting | NCT07523581 |
| Jun 30, 2027 | Ensem Therapeutics | ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrantPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Advanced Solid Tumors, Advanced Breast Cancer | Phase 1/2 | Recruiting | NCT06993844 |
| Jun 30, 2027 | Ever Supreme Bio Technology Co., Ltd. | HLA-G-CAR.BiTE allogeneic γδ T cellsA Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors | Solid Tumor | Phase 1/2 | Recruiting | NCT06150885 |
| Jun 30, 2027 | Fortvita Biologics (USA)Inc. | IBI3003A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | Phase 1/2 | Recruiting | NCT07336472 |
| Jun 30, 2027 | Roche Holding | Docetaxel, Paclitaxel, Pertuzumab and 3 moreA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With… | Neoplasm Metastasis | Phase 2 | Active not recruiting | NCT00781612 |
| Jun 30, 2027 | Hangzhou Dinovate Biotech Co., Ltd | DNV001 InjectionDNV001 Injection in Patients With Hypercholesterolemia | Primary Hypercholesterolemia | Phase 2 | Not yet recruiting | NCT07391722 |
| Jun 30, 2027 | Hangzhou Highlightll Pharmaceutical Co., Ltd | HL-300HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis | Atopic Dermatitis | Phase 1/2 | Recruiting | NCT07629778 |
| Jun 30, 2027 | Roche Holding | EntrectinibBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene R… | Breast Cancer, Cholangiocarcinoma and 14 more | Phase 2 | Active not recruiting | NCT02568267 |
| Jun 30, 2027 | Roche Holding | RO7247669Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Solid Tumors, Metastatic Melanoma and 2 more | Phase 1/2 | Active not recruiting | NCT04140500 |
| Jun 30, 2027 | Roche Holding | EntrectinibStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have … | Solid Tumors, CNS Tumors | Phase 1/2 | Active not recruiting | NCT02650401 |
| Jun 30, 2027 | ImmuneOncia Therapeutics Inc. | IMC-001A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor | TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors | Phase 2 | Recruiting | NCT06365840 |
| Jun 30, 2027 | Imunon, Inc. | Paclitaxel, Carboplatin, Bevacizumab and 1 morePhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Can… | Ovarian Cancer, Fallopian Tube Cancer and 1 more | Phase 1/2 | Recruiting | NCT05739981 |
| Jun 30, 2027 | Indaptus Therapeutics, Inc. | Decoy20, TislelizumabStudy of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | Solid Tumor, Adult, HCC - Hepatocellular Carcinoma and 6 more | Phase 1/2 | Active not recruiting | NCT05651022 |
| Jun 30, 2027 | Innovent Biologics | IBI3005, Sintilimab, Bevacizumab biosimilar and 3 moreStudy of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | Solid Tumor | Phase 1/2 | Not yet recruiting | NCT07612137 |
| Jun 30, 2027 | Innovent Biologics | Dupilumab, IBI356A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | Phase 2 | Recruiting | NCT07330934 |
| Jun 30, 2027 | Jacobio Pharmaceuticals Co., Ltd. | JAB-8263A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis (RA) | Phase 2 | Recruiting | NCT07684157 |
| Jun 30, 2027 | Johnson & Johnson | TalquetamabA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Hematological Malignancies | Phase 2 | Recruiting | NCT04634552 |
| Jun 30, 2027 | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | ACC017Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse T… | Infection, Human Immunodeficiency Virus | Phase 1/2 | Active not recruiting | NCT07711210 |
| Jun 30, 2027 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | JSKN016, DocetaxelEvaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study | Advanced Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | NCT06775483 |
| Jun 30, 2027 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | JSKN016, Capecitabine, Paclitaxel (albumin bound) and 2 moreStudy of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer | Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer | Phase 1/2 | Recruiting | NCT06942234 |
| Jun 30, 2027 | Keymed Biosciences Co.Ltd | CM338Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy | IgA Nephropathy | Phase 2 | Recruiting | NCT05775042 |
| Jun 30, 2027 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | Autologous immune Cells, Standard chemotherapyImmune Cell Therapy for Advanced Solid Tumors | Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic) and 3 more | Phase 1/2 | Not yet recruiting | NCT07260058 |
| Jun 30, 2027 | Medipost Co Ltd. | PNEUMOSTEM®, normal salineFollow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial | Bronchopulmonary Dysplasia, BPD | Phase 2 | Active not recruiting | NCT04003857 |
| Jun 30, 2027 | Metanoic Health Ltd. | ArtesunateSafety and Efficacy of Oral Artesunate for Pre-cervical Cancer | CIN 2/3 | Phase 2 | Not yet recruiting | NCT07095478 |
| Jun 30, 2027 | Montera Health Texas LLC | Tech-enabled ABA treatment planningTreatment Planning for ABA Employing Auxiliary Tools V2+ (TREAAT2+) | Autism Spectrum Disorder | Phase 1/2 | Not yet recruiting | NCT06204536 |
| Jun 30, 2027 | NaviFUS Corporation | NaviFUS SystemA Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epileps… | Drug Resistant Epilepsy, Epilepsy and 3 more | Phase 1/2 | Recruiting | NCT06388707 |
| Jun 30, 2027 | NeuroBiogen Co., Ltd | KDS2010Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia D… | Mild Cognitive Impairment (MCI), Mild Dementia and 1 more | Phase 2 | Recruiting | NCT07027072 |
| Jun 30, 2027 | Newish Biotech (Wuxi) Co., Ltd. | NWRD09 InjectionEvaluation of NWRD09 for HPV-16 Related Cervical HSIL | High-grade Squamous Intraepithelial Lesion (HSIL) | Phase 2 | Not yet recruiting | NCT07712692 |
| Jun 30, 2027 | Novartis | Rapcabtagene autoleucel single agent, IbrutinibPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and 3 more | Phase 1/2 | Active not recruiting | NCT03960840 |
| Jun 30, 2027 | NuvOx Therapeutics, Inc. | NanO2TMA Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM | Glioblastoma Multiforme | Phase 2 | Active not recruiting | NCT03862430 |
| Jun 30, 2027 | Nuvig Therapeutics, Inc. | NVG-2089Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia | Immune Thrombocytopenia (ITP) | Phase 2 | Recruiting | NCT07095127 |
| Jun 30, 2027 | Nyrada Pty Ltd | XolatrypPrevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction | Myocardial Infarction, Reperfusion Injury and 2 more | Phase 2 | Recruiting | NCT07362446 |
| Jun 30, 2027 | OncoC4, Inc. | AI-081Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT06635785 |
| Jun 30, 2027 | Otsuka Pharmaceutical | OPF-310A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1, Hypoglycemia and 15 more | Phase 1/2 | Recruiting | NCT06575426 |
| Jun 30, 2027 | Pluto Inc. | PLH-2301A Study of PLH-2301 in Subjects With Sarcopenia | Sarcopenia in Elderly | Phase 2 | Recruiting | NCT07390552 |
| Jun 30, 2027 | Prana Therapies Inc | Active PRA-216PRA-216 Atopic Dermatitis Safety and Efficacy Study | Atopic Dermatitis (AD) | Phase 2 | Not yet recruiting | NCT07810777 |
| Jun 30, 2027 | RadAlliance Therapeutics, Inc | [⁶⁴Cu]Cu-RAX301 InjectionSafety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer | Prostate Cancer | Phase 1/2 | Not yet recruiting | NCT07765940 |
| Jun 30, 2027 | RemeGen Co., Ltd. | Disitamab Vedotin, ZimberelimabA Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With R… | Cervical Cancer | Phase 2 | Recruiting | NCT06155396 |
| Jun 30, 2027 | Sclnow Biotechnology Co., Ltd. | Intravenous infusion, Intrathecal injection, umbilical cord mesenchymal stem cellUmbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia | Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2 and 2 more | Phase 2 | Not yet recruiting | NCT03378414 |
| Jun 30, 2027 | Shenyang Sunshine Pharmaceutical Co., LTD. | SSGJ-705, SSGJ-612, SSGJ-705 combined with chemotherapySSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Phase 2 | Recruiting | NCT07646626 |
| Jun 30, 2027 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SKB571 for injectionA Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnor… | Non-small Lung Cancer | Phase 2 | Recruiting | NCT07308106 |
| Jun 30, 2027 | Sumitomo Pharma | Enzomenib, azoles, Venetoclax and 3 moreA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute and 2 more | Phase 1/2 | Recruiting | NCT04988555 |
| Jun 30, 2027 | Syntrix Biosystems, Inc. | SX-682, EnzalutamideStudy of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | NCT06228053 |
| Jun 30, 2027 | TransThera Sciences (Nanjing), Inc. | Tinengotinib at the optimal dose combined with Fulvestrant, Tinengotinib, tinengotinib combined with fulvestrantEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or… | Breast Cancer | Phase 2 | Recruiting | NCT07498478 |
| Jun 30, 2027 | Transcenta Therapeutics (Hangzhou) Co., Ltd. | TST001, Nivolumab Injection [Opdivo], mFOLFOX6 and 2 moreA Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Advanced Cancer, Gastric Cancer and 2 more | Phase 1/2 | Active not recruiting | NCT04396821 |
| Jun 30, 2027 | Transcenta Therapeutics (Hangzhou) Co., Ltd. | TST001, Oxaliplatin, Capecitabine and 4 moreA Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | Advanced Cancer | Phase 1/2 | Active not recruiting | NCT04495296 |
| Jun 30, 2027 | Transcenta Therapeutics (Hangzhou) Co., Ltd. | TST003A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | Locally Advanced Solid Tumor, Metastatic Tumor and 1 more | Phase 1/2 | Active not recruiting | NCT05731271 |
| Jun 30, 2027 | VM Therapeutics LLC | VMD-3866 GelAnalgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) | Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain and 15 more | Phase 2 | Recruiting | NCT07072468 |
| Jun 30, 2027 | Wayshine Biopharm, Inc. | WSD0922-FUA Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer | EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Recruiting | NCT06631989 |
| Jun 30, 2027 | Xinnate AB | TCP-25 gelA Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa and 1 more | Phase 2 | Recruiting | NCT06594393 |
| Jun 30, 2027 | XyloCor Therapeutics, Inc. | XC001, Sham (No Treatment)Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina. | Refractory Angina, Coronary Artery Disease | Phase 2 | Recruiting | NCT07048808 |
| Jun 30, 2027 | Xyra, LLC | Budiodarone 200 mg BID, Budiodarone 400 mg BID, Budiodarone 600 mg BID and 1 moreDose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation | Atrial Fibrillation (AF), Paroxysmal AF | Phase 2 | Recruiting | NCT07792239 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.